Gastric cancer

详细信息    查看全文

• 作者：Prof Eric Van Cutsem ; MD^a ; ^{Eric.VanCutsem@uzleuven.be} ; Xavier Sagaert ; MD^b ; Prof Baki Topal ; MD^c ; Prof Karin Haustermans ; MD^d ; Hans Prenen ; MD^a
• 刊名：The Lancet
• 出版年：2016
• 出版时间：26 November-2 December 2016
• 年：2016
• 卷：388
• 期：10060
• 页码：2654-2664
• 全文大小：1117 K
• 卷排序：388

文摘

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is separated anatomically into true gastric adenocarcinomas and gastro-oesophageal-junction adenocarcinomas, and histologically into diffuse and intestinal types. Gastric cancer should be treated by teams of experts from different disciplines. Surgery is the only curative treatment. For locally advanced disease, adjuvant or neoadjuvant therapy is usually implemented in combination with surgery. In metastatic disease, outcomes are poor, with median survival being around 1 year. Targeted therapies, such as trastuzumab, an antibody against HER2 (also known as ERBB2), and the VEGFR-2 antibody ramucirumab, have been introduced. In this Seminar, we present an update of the causes, classification, diagnosis, and treatment of gastric cancer.